María Victoria
Mateos Manteca
University of Maryland, Baltimore
Baltimore, Estados UnidosPublicacións en colaboración con investigadores/as de University of Maryland, Baltimore (7)
2022
-
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
Cancer Cell, Vol. 40, Núm. 11, pp. 1358-1373.e8
2021
-
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
American Journal of Hematology, Vol. 96, Núm. 6, pp. 708-718
-
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma
Journal of Hematology and Oncology
-
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
British Journal of Haematology, Vol. 194, Núm. 3, pp. 496-507
-
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Blood Cancer Journal, Vol. 11, Núm. 12
-
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
American Journal of Hematology, Vol. 96, Núm. 9, pp. 1120-1130
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557